<div id="readability-page-1"><div>BofAS issued a report stating that BEIGENE (06160.HK) +1.100 (+0.610%) Short selling $55.62M; Ratio 15.363% recorded total sample drug sales in China of RMB602.4 million in February, up 17.7% YoY. Sales of self-developed and in-licensed products reached RMB332.2 million and RMB269.8 million, rising 20.3% YoY and 14.5% YoY, respectively. Among them, sales of tislelizumab and zanubrutinib in February were RMB244.7 million and RMB87.3 million, representing YoY growth of 14.1% and 42.6%, respectively. The broker maintained its Buy rating, with a US stock TP of USD403.8 for BEIGENE (ONC.US) and a Hong Kong stock TP of HKD243.83 for BEIGENE (06160.HK) +1.100 (+0.610%) Short selling $55.62M; Ratio 15.363% . (ha/w)(HK stocks quote is delayed for at least 15 mins.Short Selling Data as at 2026-04-27 16:25.) (Real-time Streaming US Stocks Quote; Except All OTC quotes are at least 15 minutes delayed.)</div>This article was automatically translated by AI, the Chinese version should be considered the authoritative version. AASTOCKS.com Limited does not guarantee its accuracy or completeness and accepts no liability for any damages or losses arising from the use of this translation.</div>

688235

BGNE

06160

588250

520690

520880

159316

BofAS has maintained a Buy rating on BEIGENEwith a target price of HKD243.83. The company reported total drug sales in China of RMB602.4 million in February, a 17.7% increase year-over-year. Sales of self-developed and in-licensed products were RMB332.2 million and RMB269.8 million, rising 20.3% and 14.5% YoY, respectively. Notably, tislelizumab and zanubrutinib sales reached RMB244.7 million and RMB87.3 million, showing YoY growth of 14.1% and 42.6%.

AASTOCKS News

BeOne Medicines

Beigene

BEONE MEDICINES

Penghua SSE STAR Biology and Medicine ETF

Bosera Hang Seng SCHK Innovative Drug Select ETF

Hwabao WP Hang Seng SCHK Innovative Drug Select ETF

E Fund Hang Seng SCHK Innovative Drug ETF

Bank of America

BANK OF AMERICA CORPORATION DEP SHS REP 1/1000TH INT NON CUM PFD QQ

BANK OF AMERICA CORPORATION DEP SHS REP 1/1200TH PRF SERIES '5'

BANK OF AMERICA CORPORATION 7.25% NON-CUM PERP CONV PFD SER L

BANK OF AMERICA CORPORATION 5.875%NON CUM DEP SHS REP1/1000TH SER HH

BANK OF AMERICA CORPORATION DEP SHS REP 1/1200TH PRF SERIES '2'

BANK OF AMERICA CORPORATION 5% DEP SHS REPR 1/1000TH NON CUM PFD LL

BANK OF AMERICA CORPORATION DEP SHARES REP 1/1000TH PERP PFD SER 'E'

BANK OF AMERICA CORPORATION INCOME CAPITAL OBLIG NTS DUE 15/12/2066

BANK OF AMERICA CORPORATION 4.375% DP SH RP 1/1000TH IN NON CU PF NN

BANK OF AMERICA CORPORATION DEP SH REP 1/1200TH PRF SER 1 USD25

BANK OF AMERICA CORPORATION 5.375%DEP SHS REP 1/1000TH NON CUM SR KK

BANK OF AMERICA CORPORATION 6%NON CUM DEP SHS EACH REP 1/1000 SER GG

BANK OF AMERICA CORPORATION DEP SHS REP 1/1200 PFD SER 4 USD25

BANK OF AMERICA CORPORATION DEP SHS REP 1/1000TH NON CUM PFD SER SS

BANK OF AMERICA CORPORATION 4.125%DEP SH REP 1/1000 PFD SER PP USD25

Bank of America Corp

BofAS Maintains Buy on BEIGENE  with TP at HKD243.83